A specific subtype, HER2+ (human epidermal growth factor receptor 2) is characterised by an overexpression of the HER2 oncogene [5] and accounts for 15%−30% of all breast cancers [6,7]. This evidence concerns the gene ERBB2 and breast carcinoma.